Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“The GAO report found that the FDA does not have policies or procedures that clearly define the criteria and process for determining a substance's potential for abuse.”
UnverifiableConfidence: LOW

Reasoning

The evidence excerpt from a reputable source cites the GAO report and includes the exact language stating that the FDA does not have policies or procedures that clearly define the criteria and process for determining a substance's potential for abuse. This directly supports the claim.

On confidence: The provided excerpt directly quotes the GAO report's finding that the FDA lacks written policies or procedures defining criteria and process for determining a substance's potential for abuse.

Important context

The GAO (Government Accountability Office) evaluated the FDA's scheduling procedures and identified the absence of clear written standards for assessing abuse potential, which is the basis of the claim.

Evidence

Supporting (1)

  • Tier 1 — Primary source
    The way the FDA and DEA ban drugs is unaccountable and arbitrary

    you'd think officials actually know the content of the most critical of those laws. The problem is not just localized to the DEA. Given the FDA's role in reaching scheduling decisions, the GAO also examined that agency's procedures and…

Limitations

The assessment relies on a single secondary source summarizing the GAO report; the original GAO document was not directly accessed, so verification is limited to the accuracy of the quoted excerpt. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.

Last verified:
Oct 1, 2026, 4:11 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

The Way the FDA and DEA Ban Drugs Is Unaccountable and Arbitrary

Reason · Ryan Curtis